Old Articles: <Older 7851-7860 Newer> |
|
The Motley Fool September 2, 2011 Brian D. Pacampara |
Regeneron Pharmaceuticals Shares Jumped: What You Need to Know Shares of drugmaker Regeneron Pharmaceuticals popped 10% in intraday trading Friday after The New York Times reported that Roche's age-related macular degeneration treatment Avastin led to vision loss in several California patients. |
The Motley Fool September 2, 2011 David Williamson |
When a Good Idea Goes Bad And with it go AstraZeneca's hopes of differentiation in a generic world. |
The Motley Fool September 2, 2011 Brian Orelli |
Delcath Wants a Do-Over You'd think a drug failing to show an effect would be the worst thing that could happen to a biotech investor, but mixed results are actually much worse. |
The Motley Fool September 2, 2011 Becca Lipman |
Investing 101: Rallying Health Care Stocks Being Snapped Up by the Smart Money Do you think these rallying health care stocks will continue to trade higher?: Pharmacyclics... Akorn... Endologix... Continucare... Jazz Pharmaceuticals... Seattle Genetics... Heartware International... Cubist Pharmaceuticals... Medicis Pharmaceutical... Watson... |
The Motley Fool September 2, 2011 Frank Vinluan |
Pfizer Extends Icagen Offer; Remains Just Shy of Shares Needed for Deal There's a deadline. |
The Motley Fool September 1, 2011 Dan Radovsky |
Who Will Build Your Replacement Kidney? Medical technology firms eye the future for grow-your-own body parts. |
Chemistry World September 2011 |
Column: In the pipeline Derek Lowe considers an increasingly popular business strategy in the drug industry, the much discussed 'pay for delay' deal |
The Motley Fool August 31, 2011 Brian Orelli |
Shire Enters a Crowded Market Last week, the FDA approved Shire Pharmaceuticals' Firazyr to treat a rare genetic disease. |
The Motley Fool August 31, 2011 Brian Orelli |
Antibodies: They're Not Just for Fighting Infection Anymore Therapeutic antibodies have continued to evolve since the first, OKT3, was approved back in 1986. Biotech investors had better pay attention, lest the technology passes them by. |
The Motley Fool August 31, 2011 Brian Orelli |
3 Biotechs Ready to Move Here are three biotechs with upcoming events that could drive their value higher: Exelixis... BioSante Pharmaceuticals... Amylin Pharmaceuticals... |
<Older 7851-7860 Newer> Return to current articles. |